SEQUENCE LISTING

<110> REVANCE THERAPEUTICS, INC.

<120> INJECTABLE BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE
THEREOF HAVING LONG DURATION OF THERAPEUTIC OR COSMETIC EFFECT

<130> 13720.105154PCT

<140> PCT/US2016/059492
<141> 2016-10-28

<150> 62/248,255
<151> 2015-10-29

<160> 10

<170> PatentIn version 3.5

<210> 1
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (32)..(51)
<223> This region may encompass 0-20 'Gly' residues
wherein some positions may be absent

<220>
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<400> 1
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
35 40 45

Gly Gly Gly
50

<210> 2
<211> 51
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (32)..(51)
<223> This region may encompass 0-20 'Gly' residues
wherein some positions may be absent

<220>
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<400> 2
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
35 40 45

Gly Gly Gly
50

<210> 3
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (30)..(49)
<223> This region may encompass 0-20 'Gly' residues
wherein some positions may be absent

<220>
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<400> 3
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly
            20   25   30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
        35   40   45

Gly

<210> 4
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 4
Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys Lys Lys
1   5   10   15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Lys Lys Arg Arg Gln
            20   25   30

Arg Arg Arg
        35

<210> 5
<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (21)..(45)
<223> This region may encompass 5, 7, 9, 11, 13, 15, 17, 21, 23
      or 25 'Arg' residues wherein some positions may be absent

<220>
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 5
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1   5   10   15

Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
            20   25   30

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
35 40 45

<210> 6
<211> 19
<212> PRT
<213> Drosophila sp.

<400> 6
Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp
1 5 10 15

Lys Lys Cys

<210> 7
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 7
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Tyr Gly Arg Lys
20 25 30

Lys Arg Arg Gln Arg Arg Arg
35

<210> 8
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 8
Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Gly Arg Asp
20 25 30

Asp Arg Arg Gln Arg Arg Arg
35

<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This sequence may encompass 10-20 'Lys' residues
wherein some positions may be absent

<220>
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<400> 9
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys
20

<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 10
Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg
1 5 10